A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
   PubMed Web of Science ®Google Scholar
• Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–473.
   PubMed Web of Science ®Google Scholar
• Zhang QY, Deng CL, Liu J, et al. SARS-CoV-2 replicon for high-throughput antiviral screening. J Gen Virol. 2021;102:001583.
   PubMed Web of Science ®Google Scholar
• Tani H, Kimura M, Tan L, et al. Evaluation of SARS-CoV-2 neutralizing-antibodies using a vesicular stomatitis virus-possessing SARS-CoV-2 spike protein. Virol J. 2021;18:16.
   PubMed Web of Science ®Google Scholar
• Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3:237–261.
   PubMed Web of Science ®Google Scholar
• Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–569.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422.
   PubMed Web of Science ®Google Scholar
• Bussani R, Schneider E, Zentilin L, et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine. 2020;61:103104.
   PubMed Web of Science ®Google Scholar
• Asarnow D, Wang B, Lee WH, et al. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. Cell. 2021;184:3192–3204. e16.
   PubMed Web of Science ®Google Scholar
• Algaissi A, Hashem AM. Evaluation of MERS-CoV neutralizing antibodies in sera using live virus microneutralization assay. Methods Mol Biol. 2020;2099:107–116.
   PubMedGoogle Scholar
• Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38:1073–1078.
   PubMed Web of Science ®Google Scholar
• Perri S, Greer CE, Thudium K, et al. An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-based vaccine delivery vector. J Virol. 2003;77:10394–10403.
   PubMed Web of Science ®Google Scholar
• JM P, BA B, DA D, et al. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci U S A. 1999;96:4598–4603.
   PubMed Web of Science ®Google Scholar
• Xiong C, Levis R, Shen P, et al. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science. 1989;243:1188–1191.
   PubMed Web of Science ®Google Scholar
• Schlesinger S. Alphavirus vectors: development and potential therapeutic applications. Exp Opin Biol Ther. 2001;1:177–191.
   PubMed Web of Science ®Google Scholar
• Davis NL, Caley IJ, Brown KW, et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol. 2000;74:371–378.
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Pushko P, et al. Marburg virus vaccines based upon alphavirus replicons protect Guinea pigs and nonhuman primates. Virology. 1998;251:28–37.
   PubMed Web of Science ®Google Scholar
• Pushko P, Parker M, Ludwig GV, et al. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology. 1997;239:389–401.
   PubMed Web of Science ®Google Scholar
• Zhang YN, Chen C, Deng CL, et al. A novel rabies vaccine based on infectious propagating particles derived from hybrid VEEV-Rabies replicon. EBioMedicine. 2020;56:102819.
   PubMed Web of Science ®Google Scholar
• Kinney RM, Johnson BJ, Welch JB, et al. The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. Virology. 1989;170:19–30.
   PubMed Web of Science ®Google Scholar
• Dieterle ME, Haslwanter D, Bortz RH, 3rd, et al. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. Cell Host Microbe. 2020;28:486–496. e6.
   PubMed Web of Science ®Google Scholar
• Case JB, Rothlauf PW, Chen RE, et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe. 2020;28:475–485. e5.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620.
   PubMed Web of Science ®Google Scholar
• Zhang YN, Deng CL, Li JQ, et al. Infectious Chikungunya Virus (CHIKV) with a complete capsid deletion: a new approach for a CHIKV vaccine. J Virol. 2019;93:e00504–19.
   PubMed Web of Science ®Google Scholar
• Ruiz-Guillen M, Gabev E, Quetglas JI, et al. Capsid-deficient alphaviruses generate propagative infectious microvesicles at the plasma membrane. Cell Mol Life Sci. 2016;73:3897–3916.
   PubMed Web of Science ®Google Scholar
• Case JB, Rothlauf PW, Chen RE, et al. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe. 2020;28:465–474. e4.
   PubMed Web of Science ®Google Scholar
• Cheng YW, Chao TL, Li CL, et al. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 2020;33:108254.
   PubMed Web of Science ®Google Scholar
• Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020;217:e20201181.
   PubMed Web of Science ®Google Scholar
• Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117:11727–11734.
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221–224.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280. e8.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181:894–904. e9.
   PubMed Web of Science ®Google Scholar
• He CL, Huang LY, Wang K, et al. Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products. Signal Transduct Target Ther. 2021;6:131.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;0:1–3.
   Google Scholar
• Chen Y, Zhang YN, Yan R, et al. ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker. Signal Transduct Target Ther. 2021;6:315.
   PubMed Web of Science ®Google Scholar
• Huang L, Yuen TT, Ye Z, et al. Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2. Signal Transduct Target Ther. 2021;6:168.
   PubMed Web of Science ®Google Scholar
• Khalifa SAM, Yosri N, El-Mallah MF, et al. Screening for natural and derived bio-active compounds in preclinical and clinical studies: one of the frontlines of fighting the coronaviruses pandemic. Phytomedicine. 2021;85:153311.
   PubMed Web of Science ®Google Scholar
• Pizzorno A, Padey B, Dubois J, et al. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Res. 2020;181:104878.
   PubMed Web of Science ®Google Scholar
• Zhang ZR, Zhang YN, Li XD, et al. A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2. Signal Transduct Target Ther. 2020;5:218.
   PubMed Web of Science ®Google Scholar
• Hornich BF, Grosskopf AK, Schlagowski S, et al. SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in their requirements for receptor expression and proteolytic activation. J Virol. 2021;95:e00002-21.
   PubMed Web of Science ®Google Scholar